Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Prospective, Single Arm and Open Clinical Observation of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
This PHASE2 trial investigates Antiphospholipid Syndrome and Thrombocytopenia and is currently actively recruiting participants. Institute of Hematology & Blood Diseases Hospital, China leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Mar 2025 — Present [monthly]
Recruiting PHASE2
Status: Unknown → Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Feb 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Feb 2022 — Jun 2022 [monthly]
Recruiting PHASE2
First recorded
Jan 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institute of Hematology & Blood Diseases Hospital, China
For direct contact, visit the study record on ClinicalTrials.gov .